Sorbonne Venture
Polygon Therapeutics
Polygon Therapeutics is a pioneering French startup in cardioimmunology that aims to develop an innovative biomedicine to improve the acute management of myocardial infarction.
Polygon Therapeutics has developed a monoclonal antibody that targets the immune system to prevent heart damage in ischemic cardiovascular disease. The startup aims to significantly improve outcomes in myocardial infarction and cardiovascular disease.
Activité
Research and development of a biomedicine, improvement of patient prognosis
Secteur
Biotech, Santé
Métier
Venture Deeptech
Statut
In portfolio
Date d'acquisition
2024
Montant de l'investissement
400K